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The use of the implantable cardioverter-deﬁbrillator (ICD)
has been the standard of care in the management of patients
who have experienced sudden cardiac death and also for
those patients at risk for life-threatening ventricular
arrhythmias.1 These transvenous systems carry a sub-
stantial risk of periprocedural complications including
pneumothorax, cardiac perforation, pericardial effusion or
tamponade, hemothorax, venous thrombosis, lead failure or
fracture, and infection.2,3 In 2010, Bardy et al reported the
ﬁrst successful use of a completely subcutaneous ICD
(S-ICD) that is expected to obviate these risks.4 The
U.S. Food and Drug Administration has approved the
S-ICD for use in indicated patients without the need for
ventricular pacing or cardiac resynchronization therapy.5
The S-ICD has been effective in the management of at-risk
patients; however, its use in surgical patients has been
limited. Temporary pacing and sternal wires have interfered
with normal S-ICD device function; hence, careful place-
ment of the subcutaneous lead in candidates for cardiac
surgery requiring a median sternotomy is of utmost
importance.6,7 We present the ﬁrst reported case of a patient
with an existing S-ICD system who underwent a median
sternotomy for coronary artery bypass graft (CABG)
surgery in which removal and repositioning of the S-ICD
lead was performed.KEYWORDS Ventricular tachycardia; Coronary artery bypass surgery; Implan-
table cardioverter-deﬁbrillator; Sudden cardiac arrest; Cardiomyopathy
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In February 2016, a 34-year-old man with a history of
idiopathic dilated cardiomyopathy for many years and a left
ventricular ejection fraction of 20% was referred to the
electrophysiology service for ICD implantation. He had a
history of nonsustained ventricular tachycardia and unex-
plained syncope. His electrocardiogram revealed normal
sinus rhythm without conduction abnormalities and a narrow
QRS duration. He was considered to have NYHA functional
class II heart failure symptoms on optimum medical therapy.
He underwent successful S-ICD placement and his post-
procedure course was uneventful. A chest radiograph
revealed normal S-ICD lead and generator positions and
the electrogram recording from the S-ICD lead demonstrated
normal sensing function (Figure 1). Ventricular ﬁbrillation
was induced at implantation utilizing 50 Hz stimulation from
the device and deﬁbrillation was successful with a 65 J
shock. No evidence of oversensing or undersensing was
evident.
Approximately 2 months following S-ICD implantation,
he presented to the emergency room at our institution with
acute substernal chest discomfort and shortness of breath
with new reversible anterior wall ischemia on pharmacologic
stress testing, despite the absence of a previous history of
chest pain, and despite prior negative stress test for myo-
cardial ischemia a few years earlier. Coronary angiography
revealed evidence of severe triple vessel coronary artery
disease and bypass surgery was recommended. The patient
underwent planned coronary artery bypass grafting with
speciﬁc provision for handling of the S-ICD lead that was
lying in the ﬁeld of a standard median sternotomy incision.
S-ICD lead positioning was undertaken to assure that the
distal or proximal sensing electrode was not in contact with
any sternal wires (Figure 2).
There is to date no clear guideline for managing a patient
with an existing S-ICD lead during median sternotomy, andpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.09.002
KEY TEACHING POINTS
 The subcutaneous implantable cardioverter-
deﬁbrillator (S-ICD) is useful in the prevention and
treatment of patients with life-threatening
ventricular arrhythmias and the lead system may be
repositioned safely in patients undergoing
coronary artery bypass graft surgery.
 Repositioning of the S-ICD lead in association with
the performance of a median sternotomy must be
carefully undertaken to avoid contact with
sternal wires.
 S-ICD lead testing to discriminate QRS and T-wave
amplitude ratio must be undertaken to insure
appropriate sensing to enable effective detection
and treatment of ventricular tachyarrhythmias.
Heart Rhythm Case Reports, Vol 0, No 0, Month 20162so we aim to demonstrate our effective treatment of this
clinical scenario. In anticipation that thoracic surgery in
patients with an existing S-ICD is likely to become more
frequent, given the increasing number of implanted S-ICDs,
we believe that it is essential to address an approach
to prevent potential complications related to sternal wires,
as well as other technical and electrophysiological
considerations.
Surgical technique
In the cardiothoracic surgery operating room, the patient was
prepped and draped in the standard way for CABG surgery.
Following a small paraxiphoid incision over the preexisting
incision, the anchoring sleeve of the sternal lead was located,
the suture sleeve was exposed but not freed from its
anchoring sutures, and the lead was pulled back through
this small incision to be kept outside of the body between
antibiotic-infused packing mesh. The lead was kept protected
in this manner while a standard sternotomy proceeded and
bypass surgery was performed without complication.
Following successful bypass grafting and standard closure
of the sternum with sternal wires, the subcutaneous
deﬁbrillator lead was reirrigated with antibiotic-infused
saline and replaced on top of the fascial plain overlying
the sternum, consistent with the original lead position.
The lead was nested into a central position (Figure 3) above
which the subcutaneous and skin layers were closed in
the standard fashion. Care was taken to avoid any
contact between the electrode and sternal wires to avoid
oversensing.6
Postsurgical management and device testing
Pre– and post–vector analysis of the QRS and T-wave
amplitudes was measured from the S-ICD lead and the
results met acceptable criteria along all measured vectors for
effective QRS and T-wave discrimination (Figures 1 and 2).
During postoperative in-hospital follow-up this effectiveQRS and T-wave complex discrimination remained consis-
tent with the preoperative measurements. The patient had an
uneventful postoperative course and was discharged from the
hospital after 7 days, in good condition. He returned to the
electrophysiology clinic after 1 week for an incision check,
and routinely 2 months later. All the incision sites were well
healed and the S-ICD was functioning normally, with
adequate QRS and T-wave discrimination.Discussion
To our knowledge, this is the ﬁrst detailed description of the
perioperative management of a patient with an existing S-
ICD lead who underwent CABG surgery via median
sternotomy in which explantation and reimplantation of the
same lead was performed. Additional considerations to
address involve the assessment of QRS voltage in the
immediate postoperative period, as it has been reported that
the QRS amplitude is often diminished following open chest
surgical procedures and this may interfere with QRS and
T-wave discrimination, an essential parameter that allows
accurate arrhythmia detection and minimizes the risk of
oversensing the T wave and inappropriate shocks.6–8
To avoid spurious recordings, artifacts, and oversensing,
caution should be taken to avoid placing the rate sensing
electrodes of the S-ICD lead in close proximity to sternal
wires, as this may impact sensing, particularly in the
secondary and alternate sensing vector of the device.
Infusino et al cited oversensing of epicardial pacing spikes
by the S-ICD resulting in inappropriate shocks in a patient
undergoing aortic and mitral valve replacement.7 Their
experience should serve as a caveat to clinicians when
managing patients who are at risk for bradyarrhythmias in
the perioperative period.
The S-ICD has been effective and safe in patients at risk
for sudden cardiac death who do not require antitachycardia
pacing, bradycardia support, or cardiac resynchronization
therapy.4,9–11 Traditional transvenous ICDs are associated
with an approximately 5% complication rate within 30 days
of implantation, a 16%–20% chance of lead failure over 10
years, and a 2.4% annual incidence of infection.2,3,12–14
Systemic infections and endocarditis remain a concern in the
use of these traditional devices. In addition, the risk of
infection has risen along with the increasing numbers of
invasive procedures, including generator replacement.14
Device-associated infections may have high morbidity and
mortality rates and can be fatal when associated with
bacteremia and evidence of endocarditis. Accordingly, the
extravascular nature of the S-ICD lead is expected to reduce
the potential for life-threatening infectious sequelae in these
patients.
S-ICDs can sense the QRS complex in 3 vectors, using
2 elements on the electrode—the distal tip and proximal ring
—as well as the pulse generator.10 It has been demonstrated
in this case that there was no signiﬁcant change in the sensed
QRS vector amplitude and QRS/T-wave amplitude ratio
after the median sternotomy and reimplantation of the S-ICD
Figure 1 The upper image shows the pre–coronary artery bypass graft (CABG) chest radiograph demonstrating the position of the subcutaneous implantable
cardioverter-deﬁbrillator sternal lead and generator. The upper red arrowhead points to the distal tip of the subcutaneously tunneled sensing electrode of the
sternal lead, the middle red arrowhead points to the shock coil of the lead, and the lower red arrowhead points to the subxiphoid proximal sensing electrode and
anchoring sleeve position of the lead. The long red arrow points to the transthoracic portion of the subcutaneously tunneled lead and the blue triangle points to
the implanted position of the generator of the subcutaneous deﬁbrillator. The lower pictured electrocardiogram shows a pre-CABG tracing from the lead II vector
conﬁguration of the subcutaneous recording from the distal electrodes to the can, demonstrating adequate QRS/T-wave ratio of 5:1, demonstrated by the
superimposed orange discrimination template.
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meet criteria for effective QRS/T-wave discrimination.
In this demonstrated case of lead removal and replace-
ment, the pre- and poststernotomy QRS/T-wave amplitude
ratio was adequate in all measured vectors. Even in the
immediate postoperative period when there was the highest
expectation for postsurgical thoracic impedance changes
related to pericardial and pleural effusions and inﬂammation
that could cause altered QRS/T-wave sensing and signal
differentiation, the values remained stable and optimal for
sensing. The presence of suboptimal QRS/T-wave amplitude
discrimination owing to either a small QRS complex or the
postoperative state itself may result in oversensing or
undersensing. Consequently, spurious shocks or failure to
recognize tachyarrhythmias in need of therapy may occur.We suggest that QRS amplitude surveillance should be
performed intraoperatively via the S-ICD programmer and
sternotomy closure initiated as described once the S-ICD
lead is secured and adequate sensing conﬁrmed. This will
eliminate the need to program tachycardia detection
off during the immediate in-hospital postoperative period.
If sensing function is found to be suboptimal in the
postoperative period, S-ICD tachycardia detection may be
programmed off, the patient monitored in a setting where an
external deﬁbrillator is available, and repeat evaluation
performed before discharge. Persistence of sensing
abnormalities may be managed by prescribing the use of a
wearable cardioverter-deﬁbrillator and device testing may be
repeated once postoperative healing is complete in 6 weeks
or so.15
Figure 2 The upper image shows the post–coronary artery bypass graft (CABG) chest radiograph demonstrating the position of the subcutaneous implantable
cardioverter-deﬁbrillator lead and generator. The upper red arrowhead points to the distal tip of the subcutaneously tunneled sensing electrode of the sternal lead
carefully placed to avoid any possible contact with the sternal wires that could contribute to noise sensing, the middle red arrowhead points to the shock coil of
the lead, and the lower red arrowhead points to the subxiphoid proximal sensing electrode and anchoring sleeve of the lead, which was exposed but not released
during the surgery, therefore retaining the exact same position post-CABG. The transthoracic portion of the subcutaneously tunneled lead and implanted position
of the generator of the subcutaneous deﬁbrillator remain unaltered by the surgery. The lower pictured electrocardiogram shows a post-CABG tracing from the
lead II vector conﬁguration of the subcutaneous recording from the distal electrodes to the can, demonstrating a slightly diminished but still adequate QRS/T-
wave ratio of 3:1, demonstrated by the superimposed orange discrimination template. At repeated outpatient testing post-discharge the QRS/T-wave ratio was
back to the 5:1 baseline.
Heart Rhythm Case Reports, Vol 0, No 0, Month 20164This case report demonstrates that an S-ICD lead can be
safely removed and then successfully replaced provided that
careful precautions are undertaken regarding the sternal lead
ﬁeld. The surgical technique implemented was successful in
this case and serves as a basis for deﬁning a methodological
approach to facilitate successful management of patients
with an S-ICD requiring a median sternotomy or thoracic
surgery that involves the sternal lead location.S-ICDs are being implanted far more frequently now and
this trend will continue, especially with the future potential
for leadless right ventricular pacing developments. It is
therefore likely that there will need to be established guide-
lines and recommendations for effective handling of the
device and lead during and after thoracic surgery, to allow
for continued reliable arrhythmia identiﬁcation and success-
ful deﬁbrillation therapy, when appropriate.
Figure 3 Intraoperative photograph demonstrating the post–coronary
artery bypass graft replacement of the sternal lead, after sternal wiring and
thoracic cavity closure had been completed, but before subcutaneous and
skin layers had been closed.
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